Zepbound Approved for Obstructive Sleep Apnea: What It Means

A New Indication for Tirzepatide

In June 2024, the FDA approved a new indication for tirzepatide injection 2.5 mg to 15 mg (Zepbound, Eli Lilly) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This marked the first time any pharmacological agent received FDA approval specifically for the treatment of OSA — a condition that had previously been managed almost exclusively through physical interventions such as continuous positive airway pressure (CPAP) therapy, oral appliances, and in some cases surgery.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, was already approved under the Zepbound brand name for chronic weight management and under the Mounjaro brand name for type 2 diabetes management. The sleep apnea indication extends Zepbound's clinical profile into respiratory medicine, a domain that had not previously intersected substantially with GLP-1-class drugs. Eli Lilly emphasized that the approval was intended for patients who either cannot tolerate CPAP or who wish to use Zepbound as an adjunct to existing PAP therapy.

The approval came with a notable qualification: it is intended for use as an adjunct to a reduced-calorie diet and increased physical activity, consistent with tirzepatide's existing weight-management labeling. The sleep apnea benefit is understood to be mediated substantially — though not entirely — through weight loss, as excess adipose tissue around the neck and upper airway is a primary driver of airway obstruction during sleep.

What Is Obstructive Sleep Apnea?

Obstructive sleep apnea is a common and serious sleep disorder in which the muscles at the back of the throat relax during sleep, causing the airway to narrow or close repeatedly throughout the night. Each episode — called an apnea — lasts at least ten seconds and results in a brief arousal from sleep as the brain triggers breathing to resume. In moderate-to-severe OSA, these events can occur dozens to hundreds of times per night, severely disrupting sleep architecture.

OSA is estimated to affect 30 million Americans, though it remains significantly underdiagnosed because many people are unaware that their nighttime symptoms — snoring, gasping, restless sleep — constitute a treatable medical condition. Obesity is one of the strongest risk factors for developing OSA: the additional soft tissue around the neck, combined with abdominal fat that restricts lung expansion, dramatically increases the likelihood of airway collapse during sleep. Losing even a modest amount of weight can substantially reduce OSA severity, making tirzepatide's mechanism of action particularly well-suited to addressing the root cause.

Untreated OSA is associated with a wide range of serious health consequences, including hypertension, heart failure, atrial fibrillation, type 2 diabetes, and significantly elevated risk of motor vehicle accidents due to daytime sleepiness. For patients who have struggled to adhere to CPAP therapy — a substantial proportion of those diagnosed — the availability of a pharmacological option represents a meaningful clinical alternative.

What the SURMOUNT-OSA Trial Found

The FDA approval was based on data from the SURMOUNT-OSA trial program, which comprised two parallel Phase 3 randomized, double-blind, placebo-controlled trials. SURMOUNT-OSA Study 1 enrolled participants with moderate-to-severe OSA who were not using PAP therapy, while Study 2 enrolled participants who were on established PAP therapy and continued to use it throughout the trial. Together, the two studies enrolled approximately 469 participants.

The primary endpoint in both studies was change from baseline in the apnea-hypopnea index (AHI), a measure of sleep-disordered breathing events per hour. In Study 1 (no PAP), tirzepatide reduced the AHI by approximately 25.3 events per hour compared to placebo — a 55% reduction from a baseline of roughly 51 events per hour. In Study 2 (PAP users), tirzepatide reduced AHI by approximately 29.3 events per hour compared to placebo — a reduction of approximately 62.8% from baseline.

Secondary outcomes were also impressive. Participants in the tirzepatide group showed significant improvements in self-reported sleepiness, measured by the Epworth Sleepiness Scale, as well as improvements in patient-reported sleep-related quality of life. Body weight declined by an average of approximately 20% in the tirzepatide group across both studies, consistent with weight loss data seen in the broader SURMOUNT weight-management trial program. Researchers noted that the AHI reductions were among the largest seen in any pharmacological or non-CPAP intervention for OSA.

Who Qualifies for This Treatment?

To qualify for Zepbound under the OSA indication, patients must have a confirmed diagnosis of moderate-to-severe obstructive sleep apnea — typically established through polysomnography (an in-lab sleep study) or a home sleep apnea test — and must have obesity, defined as a BMI of 30 kg/m² or greater. The indication is intended for adults only.

Patients who have not yet tried CPAP may be candidates, as may those who have tried CPAP and found it intolerable due to mask discomfort, claustrophobia, or difficulty sleeping with the device. Patients already on PAP therapy who want additional OSA control or who are looking to reduce their reliance on the device over time may also be appropriate candidates, provided their prescriber determines Zepbound is medically appropriate for their overall clinical picture.

It is important to note that Zepbound is not appropriate for all patients with OSA. Patients with central sleep apnea (CSA), which has a different neurological mechanism unrelated to airway obstruction, would not be expected to benefit from this treatment. Similarly, patients with OSA who do not have obesity fall outside the approved indication. A board-certified sleep medicine physician or obesity medicine specialist is best positioned to evaluate whether Zepbound is appropriate for any individual patient.

How Sleep Apnea Treatment Changes with Zepbound

For patients and clinicians alike, the OSA approval reframes how obesity-related comorbidities can be approached pharmacologically. Previously, treating OSA and treating obesity were largely parallel, independent efforts — a CPAP machine for the airway, dietary counseling for the weight. Zepbound now offers a single intervention that targets both the underlying excess weight and the resulting airway compromise.

Practically speaking, this could reduce or eliminate the need for CPAP in some patients who achieve sufficient weight loss and AHI improvement. The SURMOUNT-OSA data showed that a substantial proportion of tirzepatide-treated participants achieved AHI levels that would reclassify their OSA from moderate-to-severe to mild or even resolved. However, complete resolution should not be assumed — even significant weight loss does not guarantee elimination of OSA, and ongoing monitoring through repeat sleep studies is appropriate for patients making treatment transitions.

The relationship between sleep quality and GLP-1 medication success is also worth highlighting. Poor sleep drives hunger through disruptions in leptin and ghrelin signaling, raises cortisol levels, and impairs insulin sensitivity — all of which can undermine weight loss efforts. Treating OSA may therefore create a positive feedback loop: better sleep supports the metabolic and behavioral mechanisms through which tirzepatide produces weight loss, and weight loss in turn further improves sleep quality.

Insurance and Coverage Implications

The OSA indication may meaningfully improve Zepbound's insurance coverage prospects for eligible patients. Like Wegovy's cardiovascular indication, the sleep apnea approval provides insurers with a disease-specific, outcomes-backed reason to cover tirzepatide that goes beyond weight management — a category many payers have historically been reluctant to reimburse. OSA treatment is widely covered by insurance because of its clear connections to serious cardiovascular and metabolic comorbidities.

That said, coverage remains highly variable across commercial plans and is subject to prior authorization requirements. Patients seeking coverage under the OSA indication should ensure their prescribing physician documents the OSA diagnosis with supporting sleep study data, confirms obesity status, and specifies why Zepbound is being prescribed under the OSA indication rather than (or in addition to) the weight management indication. Working with a patient advocate or specialty pharmacy can also help navigate the prior authorization process more efficiently.

For patients who continue to face coverage denials, Eli Lilly's Zepbound savings card may reduce out-of-pocket costs significantly for those with commercial insurance. Patient assistance programs may also be available for those without insurance or with limited income. Consult Eli Lilly's official patient support program or speak with your pharmacy for the most current options.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Diagnosis and treatment decisions for obstructive sleep apnea should be made in consultation with a qualified sleep medicine physician, obesity medicine specialist, or other licensed healthcare provider. Always confirm current insurance coverage directly with your insurance plan and prescriber.